We believe Q2 has had a better set-up compared to prior quarters as both BD and Wound Management revenues face easier comps, which should allow Bactiguard to return to growth. However, at this stage, we believe the market is focusing on the deal flow outlook rather than the quarterly report as such and it remains to be seen if something new will be communicated on this front. Our valuation range stands at SEK 21-29.
LÄS MER
